Fig. 1From: A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimenDistribution of baseline serum IL-17A concentrations of patients with metastatic colorectal cancerBack to article page